Association of Transcranial Direct Current Stimulation (tDCS) With Gait Training With Partial Body Weight Support on the Robotic Device (Lokomat) for Treatment of Patients With Incomplete Spinal Cord Injury

University of Sao Paulo General Hospital1 site in 1 country42 target enrollmentMay 6, 2015

ConditionsSpinal Cord Injuries

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Spinal Cord Injuries
Sponsor: University of Sao Paulo General Hospital
Enrollment: 42
Locations: 1
Primary Endpoint: A. Change in the Walk Index for Spinal Cord Injury, WISCI II
Status: Completed
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The spinal cord injury is identified as the major cause of permanent disability worldwide, with the loss of ability to walk being the largest and most devastating of them for these patients. Our goal is to analyze the effects of electrical transcranial direct-current stimulation (tDCS) combined with gait training with partial body weight support aided by robotic device (Lokomat, Hocoma) in the gait of patients with incomplete spinal cord injury (SCI). In this stratified randomized double-blind study, the participants will be randomly allocated into one of both groups, outpatients (GA) or inpatients (GI), and will receive active or placebo tDCS followed by gait training with Lokomat (GA: 3 sessions/week x 10 weeks = 30 sessions; GI: 5 sessions/week x 6 weeks = 30 sessions). The functional assessments (through clinical and functional scales, assess gait, muscle strength, spasticity, balance and pain) and neurophysiological (cortical excitability measured by transcranial magnetic stimulation, electroencephalography and functional near-infrared spectroscopy) will be held before and after the training period. The functional assessments will be also held after 15 sessions (intermediate) and after 3 months follow up. The expected result is that patients that received the active tDCS presents an improvement over the ground gait after the Lokomat training period significantly greater than the placebo group, with relations between neurophysiologic, kinematics and functional measurements.

Detailed Description

The spinal cord injury is identified as the major cause of permanent disability worldwide, with the loss of ability to walk being the largest and most devastating of them for these patients. Therefore, our goal is to analyze the effects of the treatment with electrical transcranial direct-current stimulation (tDCS) associated with gait training with partial body weight support aided by robotic device (Lokomat, Hocoma) in the gait of patients with incomplete spinal cord injury (SCI) classified as AIS C and D. In this stratified randomized double-blind study, the participants will be randomly allocated into one of both groups, outpatients (GA) or inpatients (GI), and will receive active or placebo tDCS followed by gait training with Lokomat (GA: 3 sessions/week x 10 weeks = 30 sessions; GI: 5 sessions/week x 6 weeks = 30 sessions). The functional assessments (through clinical and functional scales, assess gait, muscle strength, spasticity, balance and pain) and neurophysiological (cortical excitability measured by transcranial magnetic stimulation, electroencephalography and functional near-infrared spectroscopy) will be held before and after the training period. The functional assessments will be also held after 15 sessions (intermediate) and after 3 months follow up. The expected result is that patients that received the active (tDCS) presents an improvement over the ground gait after the Lokomat training period, significantly greater than the placebo group, with positive correlation between neurophysiologic, kinematics and functional measurements.

Registry

clinicaltrials.gov

Start Date

May 6, 2015

End Date

May 5, 2018

Last Updated

4 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

University of Sao Paulo General Hospital

Responsible Party

Principal Investigator

Linamara Rizzo Battistella, MD PhD

Professor of the Medical School, USP; Chairman of the Board of Medical and Physical Rehabilitation Institute (IMREA)

University of Sao Paulo General Hospital

Eligibility Criteria

Inclusion Criteria

•Clinical and radiological diagnosis of incomplete spinal cord injury of traumatic origin;
•1 to 36 months of lesion;
•ASIA C and D;
•Stable clinical status;
•Cognitive function preserved in order to understand and execute the experiment and follow the instructions (Wechsler Adult Intelligence Scale - WASI 2014);
•Written informed consent;
•Tolerance to sit upright for at least 1 hour.

Exclusion Criteria

•Traumatic brain injury history, stroke, epilepsy and/or any other previous or concomitant neurological conditions to spinal cord injury;
•Presence of progressive neurodegenerative disease;
•Previous orthopedic problems (eg osteoarthritis, joint deformities);
•Member hypertonic (grade \> 3 on the modified Ashworth scale);
•Active/passive joint range of motion limitations;
•Irreversible muscle contractures;
•Lack of physical resistance during proposed physical training;
•Disabling fatigue;
•Body weight \> 150 Kg;
•Osteoporosis with pathological fracture risk;

Outcomes

Primary Outcomes

A. Change in the Walk Index for Spinal Cord Injury, WISCI II

Time Frame: pre (before treatment) [t0], inter (after 15 sessions) [after 5 weeks GA and after 3 weeks GI], post (after treatment) [after 10 weeks GA and after 6 weeks GI] and 3 months follow up [after 22 weeks GA and after 18 weeks GI]

Secondary Outcomes

Change in the Transcranial Magnetic Stimulation(pre (before treatment) [t0], post (after treatment) [after 10 weeks GA and after 6 weeks GI])
Change in the Lower Extremity Isokinetic Dynamometry(pre (before treatment) [t0], post (after treatment) [after 10 weeks GA and after 6 weeks GI])
Change in the Hospital Anxiety and Depression Scale - HAD(pre (before treatment) [t0], post (after treatment) [after 10 weeks GA and after 6 weeks GI] and 3 months follow up [after 22 weeks GA and after 18 weeks GI])
Change in the Beck Depression Inventory(pre (before treatment) [t0], post (after treatment) [after 10 weeks GA and after 6 weeks GI] and 3 months follow up [after 22 weeks GA and after 18 weeks GI])
Change in the Berg Balance Test(pre (before treatment) [t0],inter (after 15 sessions) [after 5 weeks GA and after 3 weeks GI], post (after treatment) [after 10 weeks GA and after 6 weeks GI] and 3 months follow up [after 22 weeks GA and after 18 weeks GI])
Change in the 10 meters Walking Test and 6 Minutes Walking test(pre (before treatment) [t0], inter (after 15 sessions) [after 5 weeks GA and after 3 weeks GI], post (after treatment) [after 10 weeks GA and after 6 weeks GI] and 3 months follow up [after 22 weeks GA and after 18 weeks GI])
Change in the Brazilian version of the McGill Pain Questionnaire(pre (before treatment) [t0], post (after treatment) [after 10 weeks GA and after 6 weeks GI] and 3 months follow up [after 22 weeks GA and after 18 weeks GI])
Change in the Pressure Algometer(pre (before treatment) [t0], inter (after 15 sessions) [after 5 weeks GA and after 3 weeks GI], post (after treatment) [after 10 weeks GA and after 6 weeks GI] and 3 months follow up [after 22 weeks GA and after 18 weeks GI])
Change in the Spinal Cord Independence Measure - SCIM(pre (before treatment) [t0], inter (after 15 sessions) [after 5 weeks GA and after 3 weeks GI], post (after treatment) [after 10 weeks GA and after 6 weeks GI] and 3 months follow up [after 22 weeks GA and after 18 weeks GI])
American Spinal Injury Association Impairment Scale - ASIA(pre (before treatment) [t0])
Change in the (Wechsler Adult Intelligence Scale - WASI 2014)(pre (before treatment) [t0], post (after treatment) [after 10 weeks GA and after 6 weeks GI] and 3 months follow up [after 22 weeks GA and after 18 weeks GI])
Change in the Ashworth Modified Scale(pre (before treatment) [t0],inter (after 15 sessions) [after 5 weeks GA and after 3 weeks GI], post (after treatment) [after 10 weeks GA and after 6 weeks GI] and 3 months follow up [after 22 weeks GA and after 18 weeks GI])
Change in the Short Form - 36 Quality of Life Test - SF 36(pre (before treatment) [t0], post (after treatment) [after 10 weeks GA and after 6 weeks GI] and 3 months follow up [after 22 weeks GA and after 18 weeks GI])
Change in the Conditioned Pain Modulation - CPM(pre (before treatment) [t0], inter (after 15 sessions) [after 5 weeks GA and after 3 weeks GI], post (after treatment) [after 10 weeks GA and after 6 weeks GI] and 3 months follow up [after 22 weeks GA and after 18 weeks GI])
Change in the Pain-Related Self-Statements Scale - Catastrophizing Subscale (PRSS-Catastrophizing)(pre (before treatment) [t0], post (after treatment) [after 10 weeks GA and after 6 weeks GI] and 3 months follow up [after 22 weeks GA and after 18 weeks GI])
Change in the Functional Near-Infrared Spectroscopy - fNIRS 16 optodes (48 channels)(pre (before treatment) [t0], post (after treatment) [after 10 weeks GA and after 6 weeks GI])
Change in the Time Up and Go Test - TUG(pre (before treatment) [t0], inter (after 15 sessions) [after 5 weeks GA and after 3 weeks GI], post (after treatment) [after 10 weeks GA and after 6 weeks GI] and 3 months follow up [after 22 weeks GA and after 18 weeks GI])
Change in the Visual Analogic Scale - VAS(pre (before treatment) [t0], inter (after 15 sessions) [after 5 weeks GA and after 3 weeks GI], post (after treatment) [after 10 weeks GA and after 6 weeks GI] and 3 months follow up [after 22 weeks GA and after 18 weeks GI])
Change in the Electroencephalography(pre (before treatment) [t0], post (after treatment) [after 10 weeks GA and after 6 weeks GI])
Change in the Patient Health Questionnaire 9 - PHQ 9(pre (before treatment) [t0], post (after treatment) [after 10 weeks GA and after 6 weeks GI] and 3 months follow up [after 22 weeks GA and after 18 weeks GI])